Peptide Lab HQ Research Guide
Ovagen
A research-focused compound profile covering Ovagen identity, EDL tripeptide research, peptide bioregulator models, cellular aging markers, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Ovagen |
|---|---|
| Common Research Name | EDL tripeptide |
| Compound Type | Synthetic ultrashort tripeptide / peptide bioregulator research compound |
| Common Sequence | Glu-Asp-Leu |
| Short Sequence | EDL |
| Amino Acid Length | 3 amino acids |
| Molecular Formula | C₁₅H₂₅N₃O₈; verify against supplier COA |
| Molecular Weight | Approximately 375.37 g/mol; verify against supplier COA |
| Research Category | Peptide bioregulator, hepatic model, gastrointestinal model, renal cell culture, cellular aging marker, gene-expression, and peptide-structure research |
| Research Context | Commonly discussed in peptide bioregulator research involving tissue-specific signaling, cellular proliferation, and cellular aging marker models. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Ovagen is commonly discussed in controlled research models involving ultrashort peptide bioregulation, EDL tripeptide signaling, cellular aging markers, renal cell-culture observations, hepatic model context, gastrointestinal model context, and gene-expression pathway research.
Peptide Bioregulator Research
Ovagen is commonly positioned within ultrashort peptide bioregulator research, where small peptide sequences are studied for tissue-specific and gene-expression related effects.
Cellular Aging Marker Models
EDL has been discussed in renal cell-culture research involving cellular aging markers such as p16, p21, p53, and SIRT-6.
Renal Cell-Culture Research
Published research describes EDL in kidney-cell culture models involving proliferation and aging-associated marker expression.
Hepatic Model Context
Ovagen is commonly discussed in peptide bioregulator references around hepatic tissue models, liver-function research context, and tissue-specific regulatory pathways.
Gastrointestinal Model Context
Ovagen is also commonly framed around gastrointestinal tissue models and digestive-system bioregulator research context.
Peptide-Structure Research
As an ultrashort tripeptide, EDL may be used in structure, solubility, stability, and peptide-interaction research under controlled laboratory conditions.
Research Scope
These applications are provided for educational and research-reference purposes only. Ovagen research is limited compared with larger clinical peptide categories, and outcomes may vary based on sequence identity, purity, study model, concentration, exposure duration, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Ovagen |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Ovagen. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a concentrated 20 mg/mL preparation, verify complete dissolution before recording final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Ovagen, commonly referenced as Glu-Asp-Leu / EDL | Ovagen is commonly discussed as a synthetic ultrashort tripeptide bioregulator in liver, gastrointestinal, and tissue-specific regulatory research contexts. |
| Peptide Bioregulator Research | Model-dependent concentration and endpoint tracking | Commonly discussed in peptide bioregulator, organ-associated peptide, chromatin-organization, gene-expression, cellular-response, and tissue-specific marker documentation. |
| Liver / Hepatic Research Context | Experimental hepatic model context | Ovagen is commonly associated with liver-cell, hepatocyte, hepatic-marker, metabolic-marker, and tissue-specific response research contexts. |
| Gastrointestinal Research Context | Digestive-tract and tissue-response model context | Research discussions often reference gastrointestinal tissue markers, digestive-tract response, cellular regulation, and peptide bioregulator model observations. |
| Cellular-Aging Marker Research | Preclinical and cell-based research context | Ovagen-related research discussions often reference cellular-aging markers, protein-expression markers, stress-response markers, and proliferation-related pathway observations. |
| Gene-Expression Research Context | DNA / peptide interaction and expression-marker context | Short peptide bioregulator literature commonly discusses DNA interaction, regulatory sequence context, and changes in gene-expression marker patterns depending on the model. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Ovagen in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 5 units / 0.05 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 10 units / 0.10 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 25 units / 0.25 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Marker Observation Window | 24–72 hours | May be used for gene-expression, hepatic-marker, gastrointestinal-marker, cellular-aging marker, protein-expression, stress-response, or peptide-response documentation depending on the model. |
| Acute Observation Window | Single session to several days | Used for early response tracking, cellular-marker comparison, peptide-response observation, or short-term pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving liver-associated, gastrointestinal, cellular-response, or gene-expression endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for cellular-aging context, liver-associated markers, gastrointestinal marker trends, or follow-up marker tracking. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Ovagen, commonly referenced as Glu-Asp-Leu / EDL, is discussed in peptide bioregulator, liver-associated, gastrointestinal, gene-expression, cellular-aging marker, chromatin-organization, protein-expression, and tissue-specific regulatory research contexts. This reference uses a 20 mg vial reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Higher-concentration preparations may require supplier-specific handling, solvent-volume, or solubility notes; verify against the COA, batch record, or formula record when available. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Ovagen is commonly discussed in research involving ultrashort peptide bioregulation, EDL tripeptide signaling, hepatic model context, gastrointestinal model context, renal cell-culture observations, cellular proliferation, and aging-associated marker expression.
Study Limitations
Ovagen research is limited compared with larger peptide categories and includes cell-culture, peptide bioregulator, and structure-focused references. Findings should be interpreted according to peptide sequence, purity, model type, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, sequence confirmation, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.